Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib.

C. Mateus,J.-P. Arnault,Gorana Tomasic,E. Hollville,Ludovic Lacroix,Janine Wechsler,B. Escudier,Alain Eychène,J.C. Soria,C. Robert

Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: Clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib.

2010

C. Mateus
J.-P. Arnault
Gorana Tomasic
E. Hollville
Ludovic Lacroix
Janine Wechsler
B. Escudier
Alain Eychène
J.C. Soria
C. Robert

9130 Background: Drugs targeting raf proteins like sorafenib or PLX4032 can induce skin neoplasms : keratoacanthomas (KA) and KA-like squamous cell carcinomas (SCC) in about 7% of the patients (pts...

Keywords:

Pathology
Sorafenib
MAPK/ERK pathway
Cancer research
Pharmacology
Medicine
multikinase inhibitor
Cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations